iZafe Group AB (publ)

Welcome to the ISEF Group's quarterly interview. With us is our CEO, Anders Sjöström. Welcome, Anders. Hello, Marius. I think we're jumping right in. I think we have many shareholders who are very curious about what has happened during Q1. So we can start right away. We see that we have had a better result despite a lower turnover. How does that look?

Men om vi tittar på förra året så skeppade vi iväg 2 500 docelynheter till våra partners och det är tack vare docelynheterna som vi gör det möjligt att få ut enheter som faktiskt hjälper personer att ta rätt medicin i rätt tid och det är när de här enheterna kommer ut och används som vi får en återkommande licensintäkt och det är den vi ser nu börjar ge effekt och i Q1 så har vi fått upp ...många enheter som börjar leverera licensintäkter. Och det är licensintäkterna vi då har bra marginal på som gör att vi kan då förbättra resultatet. Medan på hårdvaren så har vi inte så mycket marginal, det är mer en möjliggörare... And it's these licenses that we have predicted that we will close the year at at least 10 million ARR. And we closed the quarter at 3 million ARR. So we're going in the right direction and we'll keep the forecast where we put it.

Interesting. And when we talk about ARR, you mention that it's at 3 million today. What is the next milestone and how will we work to increase it?

Vi kommer att göra saker hela tiden. Dels får vi igång de här enheterna. Vi håller hela tiden på att utveckla produkter och tjänster som gör att vi kan höja vår ARPU, det vill säga snittintäkt per licens, på de som är där ute. Så att vi hittar fler tillitstjänster i de delarna. Och sen så är det såklart att få igång fler partners så att vi får upp försäljning på fler marknader. Alla de delarna bidrar till att vi höjer vår ARR. Och nästa ny stolpe, ett jämnt tal, är väl 5 miljoner. Och sen är det på hela året 10 miljoner att ha.

Very exciting. And if you read your CV, it talks a lot about the number of dispensations and how important it is for the company and how it relates to the number of units out there. Could you explain a little more about that?

Yes, but that's what makes it very real. I'm almost addicted to looking at the graphs every day, how the number of dysplasms that come out out there. That's what makes it useful, both for the patient in itself, that it is treated in medicine and the society as a whole. So that's why we exist as a company. So we follow that slavishly and look at it and see that it is increasing all the time from the week before. And it's those parts that in the end make us increase our ARR. But there we see it as the most important factor.

Very exciting. And then when you go down to the market, we see that a lot is happening in Holland now. Could you update us on what's happening there? Yes.

Holland, that's where we grow the fastest. Sweden and in the Netherlands they invest a lot in Dozell and here now a few weeks ago there was a big fair in the Netherlands where our distributor TCSN had a big Monter and it was very popular to visit our Monter there and and we notice that many who have started to think about medical robots, but also those who have worked with other types of medical robots, come there and are really impressed by how Docelle works on the Dutch market. So they brought extremely many leads. on health care companies that are interested in introducing Dosell. So it will be fun to see here in the future what it will actually give in the number of units out there and in the end, the number of dispensations where we help people take the right medicine at the right time.

Very exciting. And apart from Holland, what could you share with you of some other future prospects that are in front of us now in ISA?

Sverige fokuserar vi mycket på. Vi har många kommuner som vi går ut med i månadsbrevet. Många kommuner som har kommit igång hela tiden. Än så länge fortfarande i ganska små volymer per kommun. Självklart ligger fokus på att få varje kommun att ta in flera. Vi ser att kommunerna är väldigt nöjda hittills. Det ligger ett arbete att se till att de hittar rätt nycklar för att implementera i större skala. And then it is to continue with more municipalities in Sweden. And then we are also involved and affecting in a more general big initiative that is in Sweden, where it is signalled that there will be a big initiative called ADDA around medical robots, where we are involved in early stages to ensure that hopefully we will be involved in that initiative. And that will be a big difference in how municipalities in Sweden can call out from Then we look at Spain, where they have launched. We have the hope that it will start. It is important to know that there is no other pharmaceutical robot on the market. It is a consumer product, so it will take some time to change the behavior and make everyone understand that the product exists. They invest a lot every month in marketing, so it will have an effect in the future. And then beyond that, we have a dialogue with several upcoming partners because we want to enter more markets.

Great. Thank you, Anders. We notice that there is a lot left to prove, but we have never had better conditions than we have right now. So it will be very interesting to follow on. And thank you to all shareholders who follow along on our journey. So thank you so much. Thank you.